Download PDF
Der Klinikarzt 2011; 40(S 01): 19-23
DOI: 10.1055/s-0031-1292573
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Nur noch selten ohne Antikoagulation – Aktuelle Diagnostik und Therapie bei Vorhofflimmern und Schlaganfall

Atrial Fibrillation and stroke – diagnosis and therapy
Friedrich von Rosen
1   Schön-Klinik Bad Staffelstein
,
Anil Sinha
2   Klinikum Coburg II, Medizinische Klinik
,
Konstantin Zintl
2   Klinikum Coburg II, Medizinische Klinik
,
Christian Mahnkopf
2   Klinikum Coburg II, Medizinische Klinik
,
Peter Kühnlein
1   Schön-Klinik Bad Staffelstein
,
Harald Rittger
2   Klinikum Coburg II, Medizinische Klinik
,
Johannes Brachmann
2   Klinikum Coburg II, Medizinische Klinik
› Author Affiliations
Further Information

Publication History

Publication Date:
04 October 2011 (online)

Also available at
    Permissions and Reprints

Vorhofflimmern (VHF) ist die häufigste Ursache kardial-embolischer Hirninfarkte und wahrscheinlich auch für einen erheblichen Anteil der bisher als kryptogen bewerteten Hirninfarkte verantwortlich. Methoden zur besseren Detektion und Therapie von paroxysmalem VHF bei Schlaganfall oder transienten ischämischen Attacken (TIA) werden derzeit untersucht.

Die orale Antikoagulation (OAK) mit Warfarin und neueren Substanzen ist hochwirksam in der Prophylaxe embolischer Hirninfarkte. Nur ein geringer Anteil der Patienten mit VHF hat ein niedriges Schlaganfallrisiko und kann auf eine OAK verzichten. Zur Beurteilung des individuellen Risikos sollte der CHA2DS2-VASc-Score verwendet werden. Intrakranielle Blutungen sind die gefährlichste Nebenwirkung der OAK.

Atrial fibrillation (AF) is the main cause of cardiogenic stroke and probably also responsible for a considerable proportion of cryptogenic strokes. Methods for better detection and treatment of paroxysmal AF in stroke or TIA patients are under investigation.

Oral anticoagulation with warfarin and newer substances is highly effective in the prevention of embolic strokes. Only a small minority of AF patients is truly at low risk and can be treated without oral anticoagulation (OAC). The individual risk should be rated using the CHA2DS2-VASc-score. Intracranial bleeding is the most dangerous risk of OAC.

Key words

atrial fibrillation - stroke - anticoagulation - intracranial bleeding
 

  • Literatur

  • 1 Camm AJ, Kirchhof P, Lip YH et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010; 31: 2369-2429
    CrossrefPubMedSearch in Google Scholar
  • 2 Heuschmann PU, Busse O, Wagner M et al. Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Akt Neurol 2010; 37: 333-340
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Olesen JB, Lip YH, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation. BMJ 2011; 342
    PubMedSearch in Google Scholar
  • 4 Ezekowitz MD, James KE, Nazarian SM et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995; 92: 2178-2182
    CrossrefPubMedSearch in Google Scholar
  • 5 Knecht S, Oelschlager C, Duning T et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125-2132
    CrossrefPubMedSearch in Google Scholar
  • 6 Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia. A systematic review and meta-analysis. Stroke 2011; 76: 914-922
    PubMedSearch in Google Scholar
  • 7 www.baq-bayern.de
    PubMed
  • 8 Stahrenberg R, Weber-Kruger M, Seegers J et al. Enhanced detection of paroxymal atrial fibrillation by early and prolonged continuous Holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 2010; 41: 2884-2888
    CrossrefPubMedSearch in Google Scholar
  • 9 Gaillard N, Deltour S, Vilotijevic B et al. Detection of paroxysmal atrial fibrillation with transtelephonic EKG in TIA or stroke patients. Neurology 2010; 74: 1666-1670
    CrossrefPubMedSearch in Google Scholar
  • 10 Sinha AM, Diener HC, Morillo CA et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J 2010; 160: 36-41
    CrossrefPubMedSearch in Google Scholar
  • 11 Hart RG., Pearce LA., Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
    CrossrefPubMedSearch in Google Scholar
  • 12 Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333-2337
    CrossrefPubMedSearch in Google Scholar
  • 13 Röther J. Epidemiologie, Klinik und Management des Vorhofflimmerns. Nervenarzt 2011; 82: 159-165
    CrossrefPubMedSearch in Google Scholar
  • 14 Connolly SJ., Ezekowitz MD, Yusuf S et al. et al. RE-LY Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillations. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedSearch in Google Scholar
  • 15 Connolly SJ, Eikelboom J, Joyner C et al. AVERROES Steering Committee and Investigators. Apixaban fort he prevention of atrial fibrillation. N Engl J Med 2011; 364: 806-817
    CrossrefPubMedSearch in Google Scholar
  • 16 Holmes DR, Reddy VY, Turi ZG et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542
    CrossrefPubMedSearch in Google Scholar
  • 17 Lip GYL, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation. Stroke 2010; 41: 2731-2738
    CrossrefPubMedSearch in Google Scholar
  • 18 Adams HP, del Zoppo G., Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke. Stroke 2007; 38: 1655-1711
    CrossrefPubMedSearch in Google Scholar
  • 19 Hart RG. Management fo warfarin-associated intracerebral hemorrhage. www.uptodate.com last update September 30.09.2010
    PubMedSearch in Google Scholar
  • 20 Lip G.H.Y., Frison L., Halperin J.H., Lane D.A. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: The HAS-BLED Score. J Am Coll Cardiol 2011; 57: 173-180
    CrossrefPubMedSearch in Google Scholar
  • 21 Bösel J., Steiner T. Antagonisierung der oralen Antikoagulation bei intrakraniellen Blutungen. Dtsch Med Wochenschr 2010; 135: 2366-2369
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Morgenstern L.B., Hemphill J.C., Anderson C. et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke 2010; 41: 2108-2129
    CrossrefPubMedSearch in Google Scholar